Crinetics Pharmaceuticals Shares Rise After UBS Initiates Coverage
() -- Crinetics Pharmaceuticals (CRNX) shares rose 8% on Thursday after UBS initiated coverage of the stock with a buy rating and a price target of $55 per share. Trading volume stood at nearly 1.4 million shares compared with a daily average of more than 1.2 million. Price: $41.75, Change: $+3.07, Percent Change: +7.9